Bausch + Lomb (NYSE:BLCO) Earns Neutral Rating from Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Bausch + Lomb (NYSE:BLCO) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a neutral rating and a $16.00 target price on the stock.

BLCO has been the topic of several other reports. Zacks Research upgraded Bausch + Lomb to a “hold” rating in a research note on Tuesday, August 12th. Barclays decreased their price target on Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Monday, June 9th. Morgan Stanley increased their price objective on Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. HC Wainwright boosted their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Finally, Citigroup upped their target price on shares of Bausch + Lomb from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, July 9th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.60.

Bausch + Lomb Trading Up 3.0%

Shares of BLCO stock opened at $15.20 on Wednesday. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $21.69. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of -19.48, a P/E/G ratio of 1.50 and a beta of 0.63. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55. The firm has a fifty day moving average of $14.62 and a 200-day moving average of $13.37.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 EPS. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG bought a new stake in Bausch + Lomb during the 1st quarter worth about $50,750,000. Alberta Investment Management Corp grew its stake in shares of Bausch + Lomb by 8.6% during the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock valued at $47,360,000 after purchasing an additional 258,000 shares during the last quarter. Goldentree Asset Management LP grew its stake in shares of Bausch + Lomb by 14.9% during the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after purchasing an additional 334,916 shares during the last quarter. Oaktree Capital Management LP acquired a new stake in shares of Bausch + Lomb in the second quarter valued at approximately $32,801,000. Finally, Glenview Capital Management LLC raised its position in Bausch + Lomb by 210.8% in the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.